Featured Trial:
Melanoma Prevention Study

Featured Trial:
Breast Cancer Recurrence

Featured Trial:
Bladder Cancer Treatment

Featured Trial:
Pancreas Cancer Treatment

Featured Trial:
Stomach Cancer Treatment

Featured Trial:
Thyroid Cancer Treatment

Featured Trial:
Pancreatic Cyst Monitoring

Featured Trial:
Myeloma Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

February 13, 2026

Categories

The Winter 2026 advocacy blog Considering Clinical Trials is now available

February 9, 2026

Categories

News Stories

Natasha Edwin, MD, community co-chair of the ECOG-ACRIN Myeloma Committee, highlights why patients in rural areas need access to quality clinical trials

February 3, 2026

Categories

News Stories

ECOG-ACRIN legacy lung cancer studies E1594 and E5508 cited in ASCO Living Guideline 2026.3.0, therapy for stage 4 NSCLC without driver alterations

January 31, 2026

Categories

The January 2026 News from ECOG-ACRIN blog is now available

January 29, 2026

Categories

News Stories

Press Release: New England Journal of Medicine publishes phase 3 PATINA (PrECOG PrE0111) trial data demonstrating a significant progression-free survival benefit with palbociclib in metastatic HR+, HER2+ breast cancer

Posts

ECOG-ACRIN Cancer Research Group Follow 9,035 6,518

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

19h 2049534302472241625

.@immunosarc of @LurieCancer is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced DDLPS, UPS, & related poorly differentiated #sarcomas. More here: https://bit.ly/EA7222 cc: @CureSarcoma

Reply on Twitter 2049534302472241625 Retweet on Twitter 2049534302472241625 0 Like on Twitter 2049534302472241625 0 Twitter 2049534302472241625

ECOG-ACRIN Cancer Research Group @eaonc ·

20h 2049519218178077124

The usual treatment for #OlderAdults with early-stage #melanoma includes two surgeries. The EA6244 study asks: could one surgery + close monitoring be just as effective for some people? More info: https://bit.ly/ea6244-study cc: @YanaNajjarMD @JaniceM10

Reply on Twitter 2049519218178077124 Retweet on Twitter 2049519218178077124 0 Like on Twitter 2049519218178077124 0 Twitter 2049519218178077124

ECOG-ACRIN Cancer Research Group @eaonc ·

21h 2049504128997445930

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial

Reply on Twitter 2049504128997445930 Retweet on Twitter 2049504128997445930 0 Like on Twitter 2049504128997445930 0 Twitter 2049504128997445930

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).